SOX2 and lung cancer: In vitro, treatment of EGFR mutant lung cancer cells with erlotinib induces Sox-2 expression, with SOX2 knockdown resulting in increased erlotinib-mediated apoptosis and delayed resistance to EGFR inhibition (35).